98%
921
2 minutes
20
Recently two independent meta-analyses on the efficacy of Cognitive Bias Modification of Interpretation (CBM-I) to reduce aggressive behavior came to different conclusions: Ciesinski et al. (2023) concluded that "CBM demonstrates efficacy for the treatment of aggressive behavior" (Abstract), whereas our research team concluded that "findings show limited support for the efficacy of CBM-I to reduce aggressive behavior" (AlMoghrabi et al., 2023, Discussion). How can similar meta-analyses reach such different conclusions? In this commentary, we raise awareness concerning how 1) seemingly identical research questions can be based on meaningfully different definitions of the intervention and outcomes; 2) intervention efficacy conclusions can depend on outcome assessment type; and 3) the interpretation of underpowered moderator analyses should not depend on statistical significance. We end our commentary with a third, more nuanced conclusion that can reconcile the two disparate conclusions: that current CBM-I is an effective experimental manipulation to modify interpretation biases, but not an effective stand-alone treatment to reduce aggressive behavior.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.brat.2024.104475 | DOI Listing |
Front Oncol
August 2025
Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Introduction: Pancreatic adenocarcinoma (PAAD) is a highly aggressive malignancy characterized by a profoundly hypoxic tumor microenvironment, which fosters tumor progression and confers resistance to therapy The oncogenic regulator ID1has been implicated in PAAD malignancy, however, the mechanisms underlying hypoxia-induced stabilization of ID1 and the role of ubiquitin-mediated degradation remain poorly understood. Elucidating these pathways is essential for identifying novel therapeutic targets for PAAD.
Methods: In this study, we examined ID1 expression in PAAD tissues and cell lines using publicly available databases and in vitro models.
Cureus
August 2025
Liver Cancer Department, Binh Dan Hospital, Ho Chi Minh, VNM.
Duodenal perforation is a rare but harmful complication of endoscopic retrograde cholangiopancreatography (ERCP). Early diagnosis and appropriate management are critical to reduce morbidity and mortality. Four patients, aged 36 to 56 years, underwent ERCP for biliary obstruction due to choledocholithiasis or postoperative biliary stricture.
View Article and Find Full Text PDFCureus
August 2025
Orthopedics, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Giant cell tumor (GCT) of the bone, although benign, demonstrates local aggressiveness, a potential for recurrence, and, in rare instances, malignant transformation. Functional preservation is crucial in cases involving the articular surface, often utilizing the Sandwich Technique. We propose an enhanced reconstruction method using the inner table of the iliac crest in a reverse fashion, offering a more anatomically contoured proximal tibial plateau and reducing donor site morbidity compared to tricortical iliac crest grafting.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, 64460, Mexico.
Emerging evidence highlights the potential of bioactive compounds, particularly polyphenols, as adjunctive therapeutic agents in the treatment of pancreatic cancer (PC), one of the most aggressive malignancies. This review focuses on epigallocatechin gallate (EGCG) and resveratrol due to their extensively documented anticancer activity, favorable safety profiles, and their unique ability to modulate multiple signaling pathways relevant to pancreatic tumorigenesis. Among polyphenols, these two have shown superior anti-cancer activity, epigenetic regulatory effects, and synergy with standard chemotherapies in preclinical pancreatic cancer models.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, 00133, Italy.
Mesothelioma is a rare and aggressive cancer with a poor prognosis and limited therapeutic options. Despite recent advances, conventional treatment approaches remain largely ineffective due to late diagnosis, chemoresistance and immunosuppressive tumor microenvironment. This review reports the latest studies on combination therapies for mesothelioma, focusing on the potential of integrating chemotherapeutic agents, molecularly targeted agents, vaccines and natural bioactive compounds such as polyphenols.
View Article and Find Full Text PDF